NCT04866810 2025-10-24
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
National Institutes of Health Clinical Center (CC)
Phase NA Suspended
Clinical Trials
15 trialsNCT04418167 2025-09-03
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Phase 1 Suspended
NCT05669352 2025-04-04
A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases
University of Florida
Phase 1/2 Suspended
NCT05764395 2024-10-10
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Suspended
NCT04714983 2024-04-09
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Phase 1 Suspended
NCT03932253 2024-03-27
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1 Suspended
NCT05756556 2024-02-01
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
ImmVira Pharma Co. Ltd
Phase 2 Suspended
NCT04427306 2023-09-15
Neoadjuvant T-VEC in High Risk Early Melanoma
University of California, Davis
Phase 2 Suspended
NCT03208296 2023-02-06
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
Ascend Biopharmaceuticals Ltd
Phase 1/2 Suspended
NCT01988831 2019-05-10
Efficacy of Propranolol Treatment to Prevent Melanoma Progression
University Hospital, Geneva
Phase 2 Suspended
NCT00278122 2013-12-10
Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
University of Virginia
Phase 2 Suspended
NCT00515970 2010-06-15
Curettage Versus Excision in Nodular and Superficial Basal Cell Carcinomas
University Hospital Tuebingen
Phase NA Suspended
NCT00160992 2005-09-12
Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients
University of Lausanne Hospitals
Phase 1 Suspended
NCT00033956 2005-06-24
Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2
MetaPhore Pharmaceuticals
Phase 1/2 Suspended
NCT00042497 2005-06-24
Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma
Anosys
Phase 2 Suspended